Table 1 Main characteristics of the patients at day of inclusion.
Number of patients included | 96 |
|---|---|
Age, years (mean ± SD) | 52.6 ± 11.7 |
Body Mass Index, kg/m2 (mean ± SD) | 25.8 ± 4.4 |
Gender, n (%) male | 56 (58%) |
Ethnic origin, n (%) | |
Caucasian | 59 (61%) |
African | 34 (35%) |
Asian | 2 |
South American | 1 |
Co-administered ARV drugs | |
NRTI | ABC/3TC (n = 8), FTC/TDF (=38), 3TC (n = 17), TDF245mg (n = 8), ABC 600 (n = 1), NRTI-free (n = 25) |
NNRTI | ETR (n = 17), NVP (n = 3), EFV/FTC/TDF (n = 2) |
PI | DRV (n = 39), ATV (n = 3), LPV/r (n = 3) |
MVC | n = 13 |
CD4 cell count, cells per μl (median [min-max]) | 620 [88–1418] |
Nadir CD4 cell count, cells per μl (median [min-max]) | 119 [2–402] |
HIV-1 RNA < 40 copies per mL, n (%) | 90 (94%) |
HIV-1 RNA > 40 copies per mL, n (%) copies per mL (median [min-max]) | 6 (6%) 69 [41–152] |
Duration of treatment, months (mean ± SD) | 42.1 ± 23.7 |
Post-intake delay, hours (mean [CI95%]) | 15 [14.2–15.8] |
